Triglav Skladi D.O.O. Makes New $7.90 Million Investment in CVS Health Co. (NYSE:CVS)

Triglav Skladi D.O.O. acquired a new stake in shares of CVS Health Co. (NYSE:CVS - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 176,080 shares of the pharmacy operator's stock, valued at approximately $7,904,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Dodge & Cox grew its holdings in CVS Health by 11.2% during the fourth quarter. Dodge & Cox now owns 70,105,899 shares of the pharmacy operator's stock worth $3,147,054,000 after buying an additional 7,075,209 shares in the last quarter. Capital World Investors lifted its stake in CVS Health by 26.6% during the 4th quarter. Capital World Investors now owns 61,039,777 shares of the pharmacy operator's stock valued at $2,739,927,000 after acquiring an additional 12,819,148 shares in the last quarter. Geode Capital Management LLC lifted its stake in CVS Health by 2.6% during the 4th quarter. Geode Capital Management LLC now owns 27,051,540 shares of the pharmacy operator's stock valued at $1,211,582,000 after acquiring an additional 689,867 shares in the last quarter. Capital International Investors lifted its stake in CVS Health by 4.8% during the 4th quarter. Capital International Investors now owns 26,666,401 shares of the pharmacy operator's stock valued at $1,196,989,000 after acquiring an additional 1,212,126 shares in the last quarter. Finally, Pzena Investment Management LLC lifted its stake in CVS Health by 49.3% during the 4th quarter. Pzena Investment Management LLC now owns 19,610,579 shares of the pharmacy operator's stock valued at $880,319,000 after acquiring an additional 6,475,271 shares in the last quarter. Institutional investors own 80.66% of the company's stock.

Wall Street Analysts Forecast Growth

CVS has been the topic of several recent analyst reports. Evercore ISI raised their price objective on CVS Health from $60.00 to $65.00 and gave the company an "outperform" rating in a research note on Monday, January 27th. Barclays raised their price objective on CVS Health from $73.00 to $82.00 and gave the company an "overweight" rating in a research note on Friday, May 2nd. Royal Bank of Canada boosted their price objective on CVS Health from $74.00 to $81.00 and gave the stock an "outperform" rating in a research report on Monday, May 5th. JPMorgan Chase & Co. boosted their price objective on CVS Health from $80.00 to $81.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 18th. Finally, Wall Street Zen raised CVS Health from a "hold" rating to a "buy" rating in a research report on Friday, May 9th. Three analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $74.94.

CVS Health Stock Performance

Shares of NYSE CVS traded up $0.58 during trading on Friday, reaching $60.80. 8,141,495 shares of the stock traded hands, compared to its average volume of 11,331,035. CVS Health Co. has a 52-week low of $43.56 and a 52-week high of $72.51. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.81 and a quick ratio of 0.60. The company has a 50-day moving average of $66.15 and a 200-day moving average of $59.41. The stock has a market capitalization of $76.91 billion, a P/E ratio of 16.61, a price-to-earnings-growth ratio of 0.98 and a beta of 0.60.

CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.63. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. The firm had revenue of $94.59 billion for the quarter, compared to analysts' expectations of $93.07 billion. During the same quarter in the prior year, the firm earned $1.31 EPS. The business's revenue for the quarter was up 7.0% compared to the same quarter last year. Analysts forecast that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Tuesday, April 22nd were issued a dividend of $0.665 per share. The ex-dividend date of this dividend was Tuesday, April 22nd. This represents a $2.66 dividend on an annualized basis and a yield of 4.38%. CVS Health's dividend payout ratio (DPR) is 63.48%.

Insider Buying and Selling

In related news, SVP James David Clark sold 7,513 shares of the stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total transaction of $498,487.55. Following the sale, the senior vice president now owns 8,394 shares of the company's stock, valued at approximately $556,941.90. This represents a 47.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.22% of the stock is currently owned by insiders.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.